Investors await FDA decision on Vascepa SPA

Amarin (AMRN) is higher by 5% in premarket trading.

Investors are expecting to hear the FDA's decision on whether to reinstate the ANCHOR SPA today.

A PDUFA date was delayed last month pending consideration of the company's reinstatement request.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs